IL226157B - An antibody which specifically binds to oncostatin m and which inhibits the binding of oncostatin m to the gp130 receptor but does not directly interact with site ii residues and a pharmaceutical composition comprising the antibody for use in treating an inflammatory disorder or disease - Google Patents

An antibody which specifically binds to oncostatin m and which inhibits the binding of oncostatin m to the gp130 receptor but does not directly interact with site ii residues and a pharmaceutical composition comprising the antibody for use in treating an inflammatory disorder or disease

Info

Publication number
IL226157B
IL226157B IL226157A IL22615713A IL226157B IL 226157 B IL226157 B IL 226157B IL 226157 A IL226157 A IL 226157A IL 22615713 A IL22615713 A IL 22615713A IL 226157 B IL226157 B IL 226157B
Authority
IL
Israel
Prior art keywords
oncostatin
antibody
inhibits
receptor
residues
Prior art date
Application number
IL226157A
Other languages
English (en)
Other versions
IL226157A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45001764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL226157(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL226157A0 publication Critical patent/IL226157A0/en
Publication of IL226157B publication Critical patent/IL226157B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Volume Flow (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL226157A 2010-11-23 2013-05-05 An antibody which specifically binds to oncostatin m and which inhibits the binding of oncostatin m to the gp130 receptor but does not directly interact with site ii residues and a pharmaceutical composition comprising the antibody for use in treating an inflammatory disorder or disease IL226157B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41649510P 2010-11-23 2010-11-23
PCT/EP2011/070604 WO2012069433A2 (en) 2010-11-23 2011-11-21 Antigen binding proteins

Publications (2)

Publication Number Publication Date
IL226157A0 IL226157A0 (en) 2013-06-27
IL226157B true IL226157B (en) 2020-10-29

Family

ID=45001764

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226157A IL226157B (en) 2010-11-23 2013-05-05 An antibody which specifically binds to oncostatin m and which inhibits the binding of oncostatin m to the gp130 receptor but does not directly interact with site ii residues and a pharmaceutical composition comprising the antibody for use in treating an inflammatory disorder or disease

Country Status (40)

Country Link
US (4) US8916695B2 (ar)
EP (3) EP2643352B1 (ar)
JP (2) JP6351973B2 (ar)
KR (2) KR20130119948A (ar)
CN (1) CN103328508B (ar)
AR (1) AR083937A1 (ar)
AU (1) AU2011333878B2 (ar)
BR (1) BR112013012627A2 (ar)
CA (1) CA2818534A1 (ar)
CL (1) CL2013001466A1 (ar)
CO (1) CO6801627A2 (ar)
CY (1) CY1120448T1 (ar)
DK (1) DK2643352T3 (ar)
DO (1) DOP2013000113A (ar)
EA (1) EA027256B1 (ar)
ES (1) ES2681949T3 (ar)
HR (1) HRP20181092T1 (ar)
HU (1) HUE039412T2 (ar)
IL (1) IL226157B (ar)
JO (1) JO3455B1 (ar)
LT (1) LT2643352T (ar)
MA (1) MA34742B1 (ar)
ME (1) ME03069B (ar)
MX (1) MX351887B (ar)
MY (1) MY170404A (ar)
NZ (1) NZ610464A (ar)
PE (1) PE20140519A1 (ar)
PH (1) PH12013501036B1 (ar)
PL (1) PL2643352T3 (ar)
PT (1) PT2643352T (ar)
RS (1) RS57502B1 (ar)
SG (2) SG10201500388PA (ar)
SI (1) SI2643352T1 (ar)
SM (1) SMT201800397T1 (ar)
TR (1) TR201810773T4 (ar)
TW (1) TWI504609B (ar)
UA (1) UA111954C2 (ar)
UY (1) UY33743A (ar)
WO (1) WO2012069433A2 (ar)
ZA (1) ZA201303541B (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2814652C (en) 2010-10-13 2021-05-18 Janssen Biotech, Inc. Human oncostatin m antibodies and methods of use
EP2643352B1 (en) 2010-11-23 2018-05-02 Glaxo Group Limited Antigen binding proteins to oncostatin m (osm)
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US20170327573A1 (en) 2014-09-24 2017-11-16 Universitá Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
MX2017009695A (es) * 2015-01-29 2018-04-10 Univ Oxford Innovation Ltd Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd).
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
TW202607038A (zh) 2020-10-19 2026-02-16 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
CN1204147C (zh) 1998-02-25 2005-06-01 利思进药品公司 提高以抗体为基础的融合蛋白的循环半衰期的方法
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
ES2298106T3 (es) * 2000-04-21 2008-05-16 Conaris Research Institute Ag Proteinas de fusion que comprenden dos moleculas gp130 solubles.
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
EP1641818B1 (en) 2003-07-04 2008-12-03 Affibody AB Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
GB0407197D0 (en) * 2004-03-30 2004-05-05 Glaxo Group Ltd Immunoglobulins
SI1730191T1 (sl) * 2004-03-30 2011-11-30 Glaxo Group Ltd Imunoglobulin-vezavni hOSM
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
KR101318611B1 (ko) 2005-07-22 2013-11-13 교와 핫꼬 기린 가부시키가이샤 유전자 재조합 항체 조성물
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
AU2007267213B2 (en) * 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
WO2010056893A1 (en) * 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
CA2814652C (en) * 2010-10-13 2021-05-18 Janssen Biotech, Inc. Human oncostatin m antibodies and methods of use
EP2643352B1 (en) 2010-11-23 2018-05-02 Glaxo Group Limited Antigen binding proteins to oncostatin m (osm)

Also Published As

Publication number Publication date
UY33743A (es) 2012-06-29
MY170404A (en) 2019-07-27
US9605063B2 (en) 2017-03-28
TW201235358A (en) 2012-09-01
EP3369744A1 (en) 2018-09-05
ZA201303541B (en) 2014-11-26
EA201390537A1 (ru) 2014-01-30
EP3211009A1 (en) 2017-08-30
US20210017270A1 (en) 2021-01-21
US20170152312A1 (en) 2017-06-01
JP2014507373A (ja) 2014-03-27
DK2643352T3 (en) 2018-07-30
KR20180110199A (ko) 2018-10-08
CN103328508B (zh) 2015-12-16
PT2643352T (pt) 2018-08-01
SMT201800397T1 (it) 2018-09-13
PH12013501036A1 (en) 2013-07-15
SI2643352T1 (sl) 2018-12-31
PL2643352T3 (pl) 2018-10-31
DOP2013000113A (es) 2013-12-15
EA027256B1 (ru) 2017-07-31
EP2643352A2 (en) 2013-10-02
CA2818534A1 (en) 2012-05-31
US20150064201A1 (en) 2015-03-05
HRP20181092T1 (hr) 2018-09-21
SG10201500388PA (en) 2015-03-30
AU2011333878B2 (en) 2016-01-14
AU2011333878A1 (en) 2013-05-09
CN103328508A (zh) 2013-09-25
CL2013001466A1 (es) 2014-06-27
TWI504609B (zh) 2015-10-21
NZ610464A (en) 2015-02-27
ME03069B (me) 2019-01-20
WO2012069433A2 (en) 2012-05-31
ES2681949T3 (es) 2018-09-17
LT2643352T (lt) 2018-08-10
PH12013501036B1 (en) 2019-05-10
US8916695B2 (en) 2014-12-23
HUE039412T2 (hu) 2018-12-28
CY1120448T1 (el) 2019-07-10
UA111954C2 (uk) 2016-07-11
WO2012069433A3 (en) 2012-08-09
BR112013012627A2 (pt) 2016-10-04
JP6351973B2 (ja) 2018-07-04
MA34742B1 (fr) 2013-12-03
SG190232A1 (en) 2013-06-28
TR201810773T4 (tr) 2018-08-27
PE20140519A1 (es) 2014-04-30
US10808029B2 (en) 2020-10-20
US20130251724A1 (en) 2013-09-26
RS57502B1 (sr) 2018-10-31
IL226157A0 (en) 2013-06-27
JO3455B1 (ar) 2020-07-05
KR20130119948A (ko) 2013-11-01
MX351887B (es) 2017-11-01
KR101947356B1 (ko) 2019-02-12
CO6801627A2 (es) 2013-11-29
MX2013005843A (es) 2013-07-05
EP2643352B1 (en) 2018-05-02
JP2017078072A (ja) 2017-04-27
AR083937A1 (es) 2013-04-10

Similar Documents

Publication Publication Date Title
IL271270A (en) Antibodies to 6-il and their use
IL259979A (en) Antibodies that bind to ox40 and their uses
LTC2379594I2 (lt) Žmogaus CGRP receptorių rišantys antikūnai
IL209277A (en) Antibodies and their antigen-binding segments that bind to the interleukin antibody and interleukin 6 and interleukin 6 receptor complex
ZA201103803B (en) Antibodies to il-6 and use thereof
IL230771A (en) Antibody from a person that binds pcsk9
ZA201003467B (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
IL200572A0 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
IL221620A (en) Antagonist antibodies against the interleukin receptor 7 and methods for their use
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
SI2510011T1 (sl) Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
EP2566330A4 (en) NUCLEAR RECEPTOR BINDING ACTIVE SUBSTANCES
ZA201204213B (en) Neutralizing prolacting receptor antibodies and their therapeutic use
EP2504031A4 (en) ANTI-IL-6 ANTIBODIES AND THEIR USE
EP2626745A4 (en) TONER BINDER AND TONER COMPOSITION
IL208532A0 (en) Antibodies to il-6 and their uses
BRPI0809931A2 (pt) Antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
IL217225A0 (en) Humanised antibodies to toll - like receptor 2 and uses thereof
EP2475683A4 (en) GLUCAGONIC RECEPTOR ANTIBODY YOUR USE
EP2695897A4 (en) NEW ANTI-RECEPTOR ANTIBODY OF IL-23 HUMAN
NZ610464A (en) Antigen binding proteins to oncostatin m (osm)
EP2414392A4 (en) HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDES VCAM-1 AND COMPOSITION FOR TREATING INFLAMMATORY DISEASE OR CANCER COMPRISING THE SAME
IL229748A0 (en) Compounds that bind to human β1-adrenoceptor (ß1-ar) and their use in the measurement of ar-a1 autoantibodies

Legal Events

Date Code Title Description
FF Patent granted